Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ilex rotunda Thunb, commonly known as Kurogane holly, is a botanical species whose bark extract (Ilicis Rotundae Cortex) is utilized for its anti-inflammatory and antimicrobial properties. In clinical applications, particularly within the oral care industry in China, it is formulated into dentifrices to manage dental plaque and gingivitis. The extract's therapeutic efficacy is attributed to its rich content of triterpenoids, such as rotundic acid and pedunculoside, which inhibit the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) and modulate the NF-kappaB signaling pathway. Research conducted by institutions like Sun Yat-sen University has validated its clinical benefits in reducing gingival inflammation and plaque accumulation in adult populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ilex rotunda thunb.